Table 3.
Results of the methodological quality evaluation
| First author | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Scores |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ari(1) [12] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Fortier [13] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 16 |
| Paradisis [14] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 17 |
| Loughran [15] | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 21 |
| Ryan [16] | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 17 |
| Fletcher(1) [17] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 2 | 15 |
| Curry [18] | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 19 |
| Nagle [19] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 2 | 2 | 2 | 19 |
| Baumgart [20] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Henning [21] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 16 |
| Franco [22] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 20 |
| Kopec [23] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 16 |
| Oliveira [24] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 17 |
| Unick [25] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 17 |
| Kruse [26] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Morrin [27] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Yildiz [28] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 1 | 2 | 16 |
| Chaouachi [29] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 17 |
| Christensen [30] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 2 | 15 |
| Fletcher(2) [31] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Pagaduan [32] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 16 |
| Byrne [33] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Bafghi [34] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 1 | 2 | 17 |
| Shi Huang [35] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Baskurt [36] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 2 | 1 | 2 | 18 |
| Ari(2) [37] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Dallias [38] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 1 | 2 | 17 |
| Utku [39] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 16 |
| Jaggers [40] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 1 | 2 | 16 |
| Vetter [41] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 1 | 2 | 16 |
| Gelen [42] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
| Nelson [43] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 1 | 2 | 16 |
| Adam [44] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 1 | 2 | 17 |
| Marinho [45] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 17 |
| Perrier [46] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 18 |
“1” indicates that the purpose of the study was clearly given; “2” indicates the consistency of the patients included; “3” indicates the expected data collection; “4” indicates whether the outcome indicators reflected the purpose of the study; “5” indicates whether the trial was blinded; “6” indicates whether the follow-up period was adequate; “7” indicates whether the loss of follow-up rate was less than 5%; “8” indicates whether the sample size was estimated; “9” indicates whether the selection of the control group was appropriate; “10” indicates whether the control groups indicated whether the control groups are synchronised; “11” indicates whether the baselines were comparable between groups; “12” indicates whether the statistical analysis was appropriate